Inspire Medical Systems, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference




Inspire Medical Systems, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference

MINNEAPOLIS, Nov. 18, 2025 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Piper Sandler 37^th Annual Healthcare Conference on Tuesday, December 2, 2025.

Inspire is scheduled to present at 11:30 a.m. Eastern Time. The presentation will be accessible via a live webcast here.

A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire’s Investor website at https://investors.inspiresleep.com.

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443

Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference




Entera Bio to Participate in the 8th Annual Evercore ISI Healthcare Conference

JERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (Nasdaq: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the 8th Annual Evercore ISI Healthcare Conference, details as below.

7th Annual Evercore ISI HealthCONx Conference (Fireside Chat and 1×1 Meetings)

Date and Time: December 3 at 9:10-9:30AM in Sevilla A
Location: In person, December 3-5, 2024 Coral Gables, Florida

A live webcast of the discussion will be available at the link below. A replay will remain accessible for 90 days following the event.

Webcast Link: https://wsw.com/webcast/evercore52/entx/2393886

About Entera Bio
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab™) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.

Cautionary Statement Regarding Forward Looking Statements
Various statements in this presentation are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s forward-looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10-K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward-looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward-looking statements Entera makes in this presentation. The information in this presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

Company Contact:
Entera Bio: 
Ms. Miranda Toledano
Chief Executive Officer, Entera Bio
Email: miranda@enterabio.com

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed




Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

The Phase 2 study is designed to address regulatory approval considerations by comparing bioavailability and pharmacokinetics of NS002 against EpiPen

Previous clinical study demonstrated NS002 can achieve faster and higher absorption of epinephrine compared to an autoinjector

Dosing of the first participant in the Phase 2 study in Canada reflects the successful initiation of the Company’s needle-free epinephrine delivery program for anaphylaxis treatment

Interim results are expected in the first quarter of 2026

TEL AVIV, Nov. 18, 2025 (GLOBE NEWSWIRE) — Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical conditions, today announced the successful initiation of the Company’s Phase 2 clinical study with dosing of the first participant in Canada. The trial aims to evaluate NS002, the Company’s investigational intranasal epinephrine powder formulation, compared to EpiPen for the treatment of anaphylaxis. NS002 could potentially offer patients a needle-free alternative to traditional epinephrine autoinjectors.

The Phase 2 study is an open-label, fixed-sequence trial designed to evaluate the pharmacokinetic parameters and hemodynamic responses of NS002 compared to EpiPen in 50 healthy adults with a history of allergic rhinitis.  Interim results from this trial are expected in the first quarter of 2026.

“The dosing of the first participant in our Phase 2 study marks a significant milestone for our NS002 program and for patients with severe allergies who need more user-friendly treatment options to manage life-threatening anaphylaxis,” said Dan Teleman, Chief Executive Officer of Nasus Pharma. “We are moving forward at full speed, executing the NS002 development program as planned, and positioning the Company for its next stage of growth. For millions suffering from severe allergies, the fear of needles and the inconvenience of carrying cumbersome autoinjectors leads to poor compliance and potentially life-threatening outcomes in anaphylaxis management.”

About Nasus Pharma
Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus’s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle free, easy to use alternatives. Nasus proprietary powder-based intranasal (“PBI”) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity’s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.

Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including, among other things: statements regarding the initiation, progress, and potential outcomes of the Company’s Phase 2 clinical trial of NS002; the expected timing of interim results; the potential for NS002 to improve treatment accessibility and compliance compared to traditional autoinjectors and EpiPen; the ability of our proprietary powder-based intranasal technology to deliver epinephrine safely and effectively; the Company’s expectations for continued advancement of the NS002 development program as planned and its anticipated positioning for the next stage of corporate growth, and the advancement of NS002 as a needle-free alternative for the treatment of anaphylaxis. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company’s prospectus filed with the U.S. Securities and Exchange Commission dated August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

Company Contact
Nasus Pharma Ltd.
info@nasuspharma.com

Investor Contact
Arx Investor Relations
North American Equities Desk
nasus@arxhq.com

Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit




Rakovina Therapeutics’ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit, taking place January 27–29, 2026, in Boston, MA.

The DDR Inhibitors Summit is recognized as a premier global forum uniting translational scientists, clinicians, and biotechnology innovators working to advance next-generation DDR-targeted cancer therapies. The 2026 program will feature expert insights on synthetic lethality, emerging DDR drug targets, biomarkers, and AI-driven discovery, with a strong focus on translational strategies to accelerate clinical impact.

Prof. Daugaard will deliver a featured presentation titled:
“Harnessing AI-Driven Drug Discovery to Accelerate Next-Generation DDR Therapeutics”

His session will highlight Rakovina’s pivot to an AI-enabled drug discovery model and showcase studies of AI-designed DDR programs progressing through preclinical lead selection and toward development.

In addition to his presentation, Prof. Daugaard will participate in a fireside chat entitled “Empowering Academic Entrepreneurs to Translate DDR Discoveries Into Impactful Biotech Ventures” and a panel discussion on “Uniting Founders and Funders to Align Scientific Vision with Investment Strategy.” In these sessions, he will join a distinguished group of global oncology leaders to discuss evolving DDR biology, resistance mechanisms, and next-generation clinical strategies.

“The DDR field is undergoing a profound shift, driven by new discoveries in DNA damage response biology, smarter combination strategies, and the integration of AI into early discovery,” said Prof. Daugaard. “We are excited to contribute to the scientific dialogue shaping the future of targeted oncology, and to share how AI can accelerate the development of precisely engineered DDR therapeutics designed for clinical impact.”

As a co-founder of Rakovina and an Associate Professor at the University of British Columbia, Prof. Daugaard brings deep expertise in cancer biology and therapeutic resistance, with a research focus on uncovering vulnerabilities in tumor survival pathways and advancing them toward targeted drug discovery. His participation in the 9th DDR Inhibitors Summit reinforces the momentum behind Rakovina’s AI-accelerated DDR pipeline and highlights the Company’s role within a collaborative global effort to deliver new therapeutic options for patients with difficult-to-treat cancers.

About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking™ and Enki™ platforms. By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice Regarding Rakovina Therapeutics Forward-Looking Statements:
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved. Such statements are based on the current expectations of the management of the company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.

Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.

For Further Information Contact:
Michelle Seltenrich, BSc MBA
Director, Corporate Development
IR@rakovinatherapeutics.com
778-773-5432

A natural breakthrough in protecting cereals and field crops




A natural breakthrough in protecting cereals and field crops

Syngenta and Amoeba SA to develop and commercialize biocontrol solutions for EU and UK

Chassieu, France Basel, Switzerland , Nov. 18, 2025 (GLOBE NEWSWIRE) — Amoebas. These single-celled microorganisms are now at the heart of one of agriculture’s latest biological innovation – a bio-fungicide capable of protecting wheat and other cereal crops from crippling fungal diseases that cost global agriculture billions of dollars in annual crop losses and quality.

This new development, made from the lysate of the amoeba Willaertia magna C2c Maky, holds strong potential to advance biological crop protection. In trials, the candidate demonstrated its effectiveness in combating the fungi responsible for these fungal diseases and helped activate the plants’ defence responses. As a next‑generation biological, it is built on a biological active substance and designed to fit modern integrated crop management.  

Syngenta Crop Protection, a global leader in biologicals and other innovative crop protection technologies, and French greentech innovator Amoéba SA, have now signed a Memorandum of Understanding to develop and commercialize groundbreaking biocontrol solutions for the EU and UK markets, focusing on cereals and field crops. The parties plan to negotiate a definitive distribution agreement with a target timeline of spring 2026.This strategic collaboration aims to offer farmers advanced biological solutions that enhance the sustainability of their farming practices, address the challenge of increasing pest resistance to existing products, and offer relief to farmers facing a shrinking toolbox of crop protection technologies.

The initial focus of the partnership will be on combating the main wheat diseases, namely septoria tritici blotch (STB) and yellow rust. These two diseases are among the most economically damaging wheat diseases across Europe and the UK, impacting an estimated 9-12 million hectares of wheat annually. In Germany alone, STB causes yield losses of 5-50% and costs of €1.5 billion annually, while yellow rust can reduce yields by 10-70% and even lead to total crop failure in susceptible varieties, according to recognized industry and academic sources.

Matthew Pickard, Syngenta’s Head of Seedcare and Biologicals for Europe, said: “At Syngenta, we are committed to deliver advanced, effective biological solutions at the cutting edge of science. We’re proud to work with Amoéba to offer nature-inspired solutions that empower farmers in these important markets.”

“We are very pleased with the collaboration with Syngenta, a global leader in agricultural innovation,” affirms Benoit Villers, Chaiman of the Board of Amoéba and Jean-François Doucet, CEO of Amoéba. “This agreement, which should lead to distribution and development partnerships between our two companies, is a major step forward for Amoéba. It gives us the opportunity to combine our scientific expertise with Syngenta’s widely recognised leadership in cereal protection and the marketing of biocontrol solutions. Finally, it perfectly illustrates how collaboration between innovators in the sector can make a difference for farmers while paving the way for broader applications in field crops.”

Founded in 2010, Amoéba has developed a patented biocontrol application based on lysate from the amoeba Willaertia magna, which received the prestigious Bernard Blum Gold Medal in October 2025 as the most promising biocontrol solution worldwide. In June 2025, the active substance received EU approval following EFSA’s scientific assessment and a European Commission decision. Product-specific authorizations are in progress.

About Syngenta

Syngenta is a global leader in agricultural innovation with a presence in more than 90 countries. Syngenta is focused on developing technologies and farming practices that empower farmers, so they can make the transformation required to feed the world’s population while preserving our planet. Its bold scientific discoveries deliver better benefits for farmers and society on a bigger scale than ever before. Guided by its Sustainability Priorities, Syngenta is developing new technologies and solutions that support farmers to grow healthier plants in healthier soil with a higher yield. Syngenta Crop Protection is headquartered in Basel, Switzerland; Syngenta Seeds is headquartered in the United States. Read our stories and follow us on LinkedIn, Instagram & X.

About Amoéba

Founded in 2010, Amoéba is a greentech company based in Chassieu (Lyon, France) whose ambition is to become a major player in the treatment of microbiological risk based on the patented use of amoebae in the plant protection and cosmetics sectors.

With know-how that is unique in the world and protected by numerous patents, Amoéba is currently the only company capable of exploiting the full potential of the Willaertia amoeba on an industrial scale and cultivating it in sufficient volumes to offer biological solutions that constitute a viable alternative to the chemical products widely used today. Amoéba is currently focusing on the global biocontrol market for plant protection and on the cosmetics market. As the marketing of plant protection products is subject to obtaining local regulatory authorisations, the Company has carried out the necessary regulatory procedures and filed registration dossiers in Europe and the United States. The active substance has obtained approval in 2022 in the USA and in 2025 in Europe. Product approvals have been granted in the USA and are expected in the coming months in Europe.

The cosmetic application does not require prior approval from a competent authority in Europe or the United States. The cosmetic ingredient is already registered on the INCI (International Nomenclature of Cosmetic Ingredients) list, paving the way for it to be marketed worldwide except in China, where local approval is required.

Amoéba is listed on Euronext Growth (ALMIB). The company is a member of the Bpifrance Excellence network and is eligible for the PEA-PME scheme.

For more information, visit www.amoeba-nature.com     

Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR (“legitimate interest”). However, if you do not wish to receive further information about Syngenta, just send us a brief informal message and we will no longer process your details for this purpose. You can also find further details in our privacy statement. 

Syngenta’s Cautionary Statement Regarding Forward-Looking Statements

This document may contain forward-looking statements, which can be identified by terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’, ‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such statements may be subject to risks and uncertainties that could cause the actual results to differ materially from these statements. For Syngenta, such risks and uncertainties include risks relating to legal proceedings, regulatory approvals, new product development, increasing competition, customer credit risk, general economic and market conditions, compliance and remediation, intellectual property rights, implementation of organizational changes, impairment of intangible assets, consumer perceptions of genetically modified crops and organisms or crop protection chemicals, climatic variations, fluctuations in exchange rates and/or commodity prices, single source supply arrangements, political uncertainty, natural disasters, and breaches of data security or other disruptions of information technology. Syngenta assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

©2025 Syngenta. Rosentalstrasse 67, 4058 Basel, Switzerland.

Uma inovação natural na proteção de cereais e culturas agrícolas




Uma inovação natural na proteção de cereais e culturas agrícolas

Syngenta e Amoéba SA vão desenvolver e comercializar soluções de biocontrolo na UE e no Reino Unido

Basileia, Suíça Chassieu, França, Nov. 18, 2025 (GLOBE NEWSWIRE) — Uma inovação natural na proteção de cereais e culturas agrícolas

Syngenta e Amoéba SA vão desenvolver e comercializar soluções de biocontrolo na UE e no Reino Unido

As amebas, microrganismos unicelulares, estão hoje no centro de uma das mais recentes inovações biológicas aplicadas à agricultura : um biofungicida capaz de proteger o trigo e outros cereais contra doenças fúngicas devastadoras, responsáveis de perdas anuais de milhares de milhões de dólares em quebras de produção e redução da qualidade das colheitas.

Este novo produto, fabricado a partir do lisado da ameba Willaertia magna C2c Maky, apresenta um forte potencial para fazer evoluir a proteção biológica das culturas. Durante os ensaois realizados, a solução demonstrou eficácia contra os fungos causadores dessas doenças e mostrou capacidade para ativar os mecanismos naturais de defesa das plantas. Trata-se de uma solução biológica de nova geração, desenvolvida a partir de uma substância ativa natural e concebida para se integrar plenamente na gestão agrícola moderna.

Syngenta Crop Protection, líder mundial em biocontrolo e tecnologias inovadoras de proteção das culturas, e Amoéba SA, uma greentech francesa de referência, assinaram um Memorando de Entendimento para desenvolver e comercializar soluções inovadoras de biocontrolo destinadas aos mercados da União Europeia e do Reino Unido, com prioridade para os cereais e as grandes culturas. As duas empresas tencionam concluir um acordo de distribuição definitivo até à primavera de 2026.
Este acordo estratégico pretende oferecer aos agricultores uma nova geração de soluções biológicas que reforcem a sustentabilidade das práticas agrícolas, respondam ao desafio crescente da resistência aos produtos convencionais, e contribuem para facilitar o trabalho dos agricultores, que dispõem de cada vez menos opções para proteger as suas culturas.

Numa primeira fase, o foco incidirá no combate às principais doenças do trigo: a septoriose (STB) e a ferrugem amarela. Ambas estão entre as doenças mais prejudiciais económica­mente para o trigo na Europa e no Reino Unido, afetando anualmente cerca de 9 a 12 milhões de hectares. Só na Alemanha, a STB provoca perdas de rendimento que variam entre 5% e 50% e representa um custo anual de 1,5 mil milhões de euros, enquanto a ferrugem amarela pode reduzir a produção em 10% a 70%, podendo mesmo destruir totalmente as colheitas das variedades suscetíveis, segundo fontes industriais e académicas de referência.

Matthew Pickard, responsável Proteção de sementes e Produtos biológicos da Syngenta na Europa, afirma: « Na Syngenta, estamos empenhados em disponibilizar soluções biológicas de nova geração, eficazes e alinhadas com os mais recentes avanços científicos. É um orgulho colaborar com a Amoéba para desenvolver soluções inspiradas na natureza que tragam verdadeiro valor aos agricultores destes mercados-chave. »

« Estamos muito satisfeitos desta colaboração com a Syngenta, líder mundial em inovação agrícola», acrescentam Benoit Villers, Président do Conselho de administração da Amoéba, e Jean-François Doucet, Diretor-geral da Amoéba. «Este acordo, que deverá conduzir a parcerias de desenvolvimento e distribuição entre as duas empresas, representa uma etapa determinante para a Amoéba. Permite-nos combinar a nossa experiência científica com a reconhecida liderança da Syngenta na proteção dos cereais e no mercado do biocontrolo, abrindo caminho a aplicações mais amplas nas grandes culturas.»

Fundada em 2010, a Amoéba desenvolveu uma solução de biocontrolo patenteada baseada no lisado da amiba Willaertia magna, distinguida com a prestigiada Medalha de ouro Bernard Blum em outubro de 2025 como a solução de biocontrolo mais promissora a nível mundial. Em junho de 2025, a substância ativa recebeu aprovação da UE, após avaliação científica da EFSA e decisão da Comissão Europeia. As autorizações específicas de produto estão atualmente em curso.

Sobre a Syngenta

A Syngenta é uma empresa líder mundial em inovação agrícola, presente em mais de 90 países. A sua missão é desenvolver tecnologias e práticas que permitam aos agricultores produzir alimentos para uma população mundial crescente, protegendo simultaneamente o planeta. As suas descobertas científicas proporcionam benefícios inéditos aos agricultores e à sociedade, numa escala nunca antes vista. Guiada pelas suas prioridades de sustentabilidade , Syngenta desenvolve soluções que ajudam a cultivar plantas mais saudáveis em solos mais resilientes e com maior produtividade. A Syngenta Crop Protection está sediada em Basileia, Suíça, enquanto a Syngenta Seeds tem sede nos Estados Unidos. Acompanhe as nossas histórias no LinkedIn, Instagram e X.

Sobre a Amoéba

Fundada em 2010, a Amoéba é uma empresa de tecnologia verde sediada em Chassieu (Lyon, França) que tem como objetivo tornar-se um dos principais intervenientes no tratamento do risco microbiológico através da exploração patenteada de amebas nos setores da proteção de plantas e dos cosméticos.

Com uma experiência única no mundo, protegido por inúmeras patentes, a Amoéba é hoje a única empresa capaz de explorar em escala industrial todo o potencial da ameba Willaertia e cultivá-la em volumes suficientes para oferecer soluções biológicas que constituem uma alternativa viável aos produtos químicos amplamente utilizados atualmente. A Amoéba concentra-se atualmente no mercado mundial de biocontrolo para a proteção de plantas e no mercado de cosméticos. Uma vez que a comercialização de produtos fitossanitários está sujeita à obtenção de autorizações regulamentares locais, a empresa obteve a autorização de comercialização nos Estados Unidos e os trâmites regulamentares necessários estão em curso em vários países da Europa. No que diz respeito à substância ativa, ela já obteve em 2022 a aprovação nos EUA e o relatório positivo e definitivo da EFSA na Europa em junho de 2025. As autorizações de comercialização foram concedidas nos Estados Unidos e são esperadas nos próximos meses na Europa.

No que diz respeito à aplicação cosmética, esta última não requer aprovação prévia de uma autoridade competente na Europa e nos Estados Unidos. O ingrediente cosmético já está inscrito na lista INCI (International Nomenclature of Cosmetic Ingredients), abrindo caminho para a sua comercialização em todo o mundo, exceto na China, onde é necessária uma homologação local.

A Amoéba está cotada na Euronext Growth (ALMIB), integra a rede Bpifrance Excellence e é elegível para o regime PEA-PME.

Mais informações em www.amoeba-nature.com

A proteção de dados é importante para nós. Recebe esta publicação com base jurídica no artigo 6.º, n.º 1, alínea f) do RGPD («interesse legítimo»). No entanto, se não desejar continuar a receber informações sobre a Syngenta, basta enviar-nos uma breve mensagem informal e deixaremos de tratar os seus dados para esse fim. Encontrará mais informações na nossa declaração de privacidade.

Aviso da Syngenta sobre declarações prospectivas

Este documento pode conter declarações prospectivas, que podem ser identificadas por termos como «esperar», «poder», «será», «potencial», «prever», «perspetivas», «estimado», «visar», «no bom caminho» e outras expressões semelhantes. Essas declarações podem estar sujeitas a riscos e incertezas que podem fazer com que os resultados reais difiram significativamente dessas declarações. Para a Syngenta, esses riscos e incertezas incluem riscos relacionados a processos judiciais, aprovações regulatórias, desenvolvimento de novos produtos, aumento da concorrência, risco de crédito do cliente, condições econômicas e de mercado gerais, conformidade e remediação, direitos de propriedade intelectual, implementação de mudanças organizacionais, depreciação de ativos intangíveis, percepção dos consumidores sobre culturas e organismos geneticamente modificados ou produtos químicos de proteção de culturas, variações climáticas, flutuações nas taxas de câmbio e/ou preços de matérias-primas, acordos de fornecimento de fonte única, incerteza política, catástrofes naturais e violações de segurança de dados ou outras perturbações das tecnologias da informação. A Syngenta não assume qualquer obrigação de atualizar as declarações prospectivas para refletir os resultados reais, alterações nas hipóteses ou outros fatores.

©2025 Syngenta. Rosentalstrasse 67, 4058 Basileia, Suíça.

HelixAI launches a new agentic operating system to bring the power of autonomous AI to life sciences




HelixAI launches a new agentic operating system to bring the power of autonomous AI to life sciences

PRESS RELEASE

• New operating system enables scientists to move from copilot to autopilot, unifying diverse in silico, wet lab research and scientists to accelerate innovation
• Partnerships with NVIDIA, AWS and Sapio Sciences and over 100 in silico tool providers allow access to leading agentic tools with enterprise-grade security, data traceability and compliance
• HelixAI is led by an AI native team with experience from Astellas, McKinsey &Co, and Causaly, supported by the leading international healthcare investment advisor, GHO Capital

Fort Lauderdale, Florida, USA, November 18, 2025 – HelixAI, a life science AI company creating an agentic operating system to transform R&D, launches its first-in-class agentic OS today at the AI Driven Drug Discovery Summit (AIDDD) in Boston, Massachusetts.

The platform is designed to enable life sciences companies to achieve the innovation promise of AI by focusing on insight, not process. AI uptake is at a tipping point in life science R&D organizations, with spending predicted to accelerate from $4 billion in 2025 to $20 billion by 2030¹. This is already reducing preclinical drug development timelines by up to 40%² in some instances, and investment in autonomous lab platforms is accelerating sharply.

But scientists are feeling overwhelmed by 300+ R&D AI products and hundreds of open source tools now available in life science R&D³. The volume and speed of innovation creates challenges for biopharma teams to test, scale and implement these tools, often leading to low adoption and inertia among scientists.

HelixAI has created the first agentic operating system which facilitates the straightforward construction of intricate pipelines incorporating open-source tools, commercial products, customer developed agents, scientists input, and laboratories. This system operates as a fully automated pipeline, maintaining complete data traceability for all executed work, including the inputs and outputs of every step.

The HelixAI platform takes the pain out of using multiple tools and agents, autonomously executing advanced in silico workflows and seamlessly integrating these with feedback from in vitro wet laboratory testing, including lab-in-the-loop and closed loop research infrastructure. This turns what’s now a convoluted, multi-step process into a single, efficient and iterative activity to enable scientists to focus on accelerated discovery, ultimately enabling them to get better medicines to market faster.

The HelixAI operating system features enterprise-quality security with full data traceability and compliance, while providing access to world class compute and over 100 embedded tools. This comprehensive capability is enabled through strategic partnerships with NVIDIA, AWS, and Sapio Sciences and an extensive network of partners including Simulations Plus, CCDC, Cadence Molecular Sciences (OpenEye), Optibrium, and DISGENET – all designed to integrate seamlessly with a company’s own R&D agents.

Kevin Cramer, Founder and CEO of HelixAI, commented: “The biopharma industry is investing heavily in powerful in-silico R&D tools that are under-utilized because they’re often too difficult to operate or operate at scale. Biopharma research leaders need a way to connect discovery pipelines and integrate the various agents their teams are building. HelixAI democratizes access to these pipelines and tools for scientists with an agentic operating system that works with unprecedented autonomy, moving life science R&D from copilot to autopilot and allowing teams to focus on innovation.”

“A critical oversight in current practices is the provision of tools to scientists without comprehensive traceability of tool calls, inputs, and outputs. This lack of oversight poses a significant risk of intellectual property issues in the future if left unaddressed. The HelixAI team recognizes these challenges faced by R&D organizations and has engineered an enterprise-ready platform that delivers complete security, data traceability, compliance, and robust compute power. HelixAI is purpose-built for the life sciences sector, designed to simplify AI implementation, thereby enabling teams to substantially scale in silico science for the accelerated delivery of improved therapeutic agents.”

“Democratizing access to AI is a fundamental part of our philosophy at AWS,” added Jason Decker, Data and AI Sales Leader at AWS. “By working with HelixAI, we’re giving life sciences organizations of all sizes access to proven compute infrastructure and advanced AI and analytics capabilities that underpin innovation in research.”

References

1. Fierce Biotech and Deloitte, March 2025
2. BCG BioPharma trends, January 2025
3. Merelogic, October 2025

-Ends-

For more information please contact:

HelixAI
Kevin Cramer, Founder and CEO
Mike Hampton, Chief Commercial Officer           
Dave Cooney, Head of GTM
info@helixai.com

To book a demonstration of our operating system please contact:
Dave.cooney@helixai.com

About HelixAI

HelixAI is dedicated to transforming R&D by unifying tools and autonomous processes in a single platform, enabling scientists to deliver better medicines, faster.

We have created the first true agentic operating system for R&D, allowing research to move from copilot to autopilot. We enable the creation of seamless in silico workflows with true wet lab integration. By integrating scientific data from public, private and client sources with unlimited autonomous computation, HelixAI takes the pain out of pipeline creation, closing the loop between computation and the bench, and putting human scientists into the driving seat.

HelixAI is led by a team with decades of experience in science and bioinformatics and backed by one of Europe’s leading healthcare investors, GHO Capital.

Find out more online at: https://www.helixai.com  

Follow us on LinkedIn.

Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer




Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer

VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics today announced the appointment of Scott Platshon as Acting Chief Investment Officer.

Mr. Platshon will report directly to Zymeworks’ Chair and Chief Executive Officer, Kenneth Galbraith, and work closely with him to manage expected future cash flows from Ziihera® (zanidatamab-hrii) and other healthcare assets and licensed product candidates, such as pasritamig, which is being advanced to Phase 3 registration studies by Johnson & Johnson Innovative Medicine. He will also manage the operational execution of Zymeworks’ healthcare asset aggregation strategy.

Concurrent with this appointment, Mr. Platshon has stepped down from the Company’s Board of Directors. As this is a part-time role, he will also continue to serve as a Partner at EcoR1 Capital, LLC, a biotech-focused investment fund.

“Following the positive topline data from the Phase 3 HERIZON-GEA-01 trial evaluating zanidatamab in combination with chemotherapy with or without the PD-1 inhibitor Tevimbra® (tislelizumab), we are strategically positioned to drive long-term returns by building a diversified portfolio of revenue-generating assets,” said Mr. Galbraith. “Scott has played a key role in managing EcoR1’s investment in Zymeworks, including joining our Board in February 2024. He has been working closely with me and the Board to complement our active R&D operations with a novel strategic initiative of actively managing and aggregating revenue-generating assets to generate attractive long-term shareholder returns from an integrated business approach. Scott’s deep investment expertise, in-depth knowledge of the Company and our strategic objectives, and global network make him uniquely suited to help accelerate these efforts and protect and manage value arising from our royalty portfolio.”

Mr. Platshon has worked at EcoR1 Capital since 2015, and served as a Partner since 2020. Prior to joining the firm, he was an analyst at Aquilo Partners, a San Francisco-based boutique life sciences investment bank. Mr. Platshon also sits on the board of directors of Kumquat Biosciences and Ajax Therapeutics. Mr. Platshon holds a B.S. in Bioengineering from Stanford University.

“I am eager to continue working closely with Zymeworks, now in this new role, at such a pivotal moment, and share in the Company’s unified strategic vision to pursue innovation and growth,” said Scott Platshon. “The Company has built a strong financial foundation with Ziihera, its broader platform collaborations and wholly-owned R&D portfolio, and I see tremendous opportunity to leverage these cash flows to build a disciplined, high-return portfolio that creates sustainable value creation over the long-term. I look forward to enhancing my involvement within the Zymeworks team and forging new capital streams to deliver meaningful returns for shareholders.”

About Zymeworks Inc.

Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. The Company’s asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera® (zanidatamab-hrii), pasritamig, and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is also building a portfolio of healthcare assets that can generate strong cash flows, while supporting the early-stage development of innovative medicines. Zymeworks engineered and developed Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ expectations regarding implementation of its strategic priorities and the anticipated benefits thereof, including shareholder returns and the anticipated manner of such returns; implementation of its evolving asset aggregation strategy, including existing and potential future royalty streams and existing and potential new partnerships; statements that relate to the expected contributions of personnel to Zymeworks’ strategic goals; the anticipated benefits of its collaboration agreements, including Zymeworks’ ability to receive any future milestone payments and royalties thereunder; anticipated capital allocation strategy; industry opportunities for acquisition of new revenue streams or collaborations; the potential addressable market of zanidatamab; expected financial performance and future financial position; the commercial potential of technology platforms and product candidates; Zymeworks’ ability to satisfy potential regulatory and commercial milestones with existing and future partners; anticipated continued receipt of revenue from existing and future partners; Zymeworks’ early-stage pipeline and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “on track”, “progress”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; Zymeworks may not achieve milestones or receive additional payments under its collaborations; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of new or changing laws and regulations; market conditions, including the impact of tariffs; potential negative impacts of FDA regulatory delays and uncertainty around recent policy developments, changes in the leadership of federal agencies such as the FDA, staff layoffs, budget cuts to agency programs and research, and changes in drug pricing controls; the impact of pandemics and other health crises on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf; zanidatamab may not be successfully commercialized; Zymeworks’ evolution of its business strategy related to anticipated and potential future milestones and royalty streams and existing and potential new partnerships may not be successfully implemented; Zymeworks’ evolution of its business strategy may not deliver meaningful shareholder returns; Zymeworks may be unsuccessful in actively managing and/or aggregating revenue-generating assets alongside its active R&D operations; ongoing and future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; Zymeworks’ assumptions and estimates regarding its financial condition, future financial performance and estimated cash runway may be incorrect; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the Securities and Exchange Commission (copies of which may be obtained at www.sec.gov and www.sedarplus.ca).

Although Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.

Investor inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com

Media inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

Apollomics Announces Changes to its Board of Directors and Composition of Committees




Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees.

On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company.

Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes and the previously announced appointments of directors, the Company’s Board is comprised of the following seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors.

Biographical Information of the New Director

Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan’s biopharmaceutical industry.

Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics.

Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond’s portfolio companies. She participated in Diamond Biofund’s IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities’ investment banking profits.

Dr. Huang’s scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.

Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.

About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

CONTACT: Investor Contacts:

Apollomics:
Peter Lin, Chief Financial Officer
Apollomics, Inc.
Phone: 1-650-209-4055
Email: peter.lin@apollomicsinc.com

Apollomics Announces Changes to its Board of Directors and Composition of Committees




Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding changes to the Company’s board of directors (“Board”) and composition of committees.

On November 16, 2025, Mr. Po-Jen Hsueh resigned from the Board. Mr. Hsueh’s resignation was not related to any disagreement with the Company.

Pursuant to a meeting of the Board on November 16, 2025, Dr. Ya-Chi (Claudia) Huang was appointed to the Board to fill the vacancy resulting from Mr. Hsueh’s resignation. Dr. Ya-Chi (Claudia) Huang will also replace Mr. Po-Jen Hsueh as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee. Following these changes and the previously announced appointments of directors, the Company’s Board is comprised of the following seven members: Hung-Wen (Howard) Chen (Chairman), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang. Moses Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang are independent directors.

Biographical Information of the New Director

Dr. Ya-Chi (Claudia) Huang brings to the Board extensive experience in biotechnology investment, corporate governance, and research and development across Taiwan’s biopharmaceutical industry.

Dr. Huang currently serves as Assistant Vice President at Maxpro Ventures, where she leads domestic and international investment activities. Since joining in 2024, she has successfully completed investments in multiple companies and manages their post-investment operations. She also serves as a director of AngenMed Therapeutics.

Previously, Dr. Huang served as Investment Manager at Diamond Biofund (6901.TW), where she independently completed multiple investments and oversaw post-investment management for all of Diamond’s portfolio companies. She participated in Diamond Biofund’s IPO on the Taiwan Stock Exchange in 2023. Earlier in her career, she was Deputy Manager in the Research Department at Fubon Securities Investment Services, where she evaluated over 150 unlisted biotech companies in Taiwan, China, and Hong Kong, and contributed to a significant increase in Fubon Securities’ investment banking profits.

Dr. Huang’s scientific background includes research positions at the National Health Research Institutes, Development Center for Biotechnology, and Academia Sinica. Her doctoral research on Epstein-Barr virus was published in Blood and received the Distinguished Thesis Prize in the 12th TienTe Lee Biomedical Award.

Dr. Huang holds a Ph.D. in Microbiology from National Taiwan University College of Medicine and an M.S. in Biological Sciences from National Sun Yat-sen University.

About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries. For more information, please visit www.apollomicsinc.com.

Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.

CONTACT: Investor Contacts:

Apollomics:
Peter Lin, Chief Financial Officer
Apollomics, Inc.
Phone: 1-650-209-4055
Email: peter.lin@apollomicsinc.com